Stockwatch: Supporting acts to the rescue
This article was originally published in Scrip
Executive Summary
Three months ago, the resounding take-home message from the full year 2010 financial results three months ago was that the environment had not been good and caution surrounded 2011. That theme was mollified during the last week of April when a large number of biotech and pharmaceutical companies, big and small, reported better than expected first quarter 2011 financial results. However, reading between their (sales) lines, it was often not the pharmaceutical divisions amongst pharmaceutical companies that have snatched a recovery from the jaws of last year’s defeat.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.